Royal Bank Of Canada Gemini Therapeutics, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.31 - $2.01 $171 - $263	131 New	131 $0
Q2 2022 Aug 15, 2022	SELL	$1.22 - $1.73 $1,917 - $2,719	-1,572 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.29 - $3.08 $4,258 - $10,167	-3,301 Reduced 67.74%	1,572 $2,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $4.0 $7,126 - $11,928	2,982 Added 157.69%	4,873 $14,000
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.32 $1,290 - $2,471	391 Added 26.07%	1,891 $7,000
Q2 2021 Aug 16, 2021	BUY	$6.32 - $14.02 $9,480 - $21,030	1,500 New	1,500 $10,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.